1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Diagnostics and Therapeutics for Lung Cancer: Global Markets

This BCC Research report analyzes the market for diagnostics and therapeutics for lung cancer, and also focuses on regulations and reimbursements affecting diagnostics tests and drugs used in therapeutics.

Use this report to:
- Analyze market revenues of the global lung cancer market segments and subsegments based on geographies and products.
- Identify regulations and government supported programs impacting the lung cancer market.
- Learn about various lung cancer diagnostics tests and lung cancer therapeutics like chemotherapy, radiotherapy and surgery.

Highlights
- The global market for lung cancer grew to $21.9 billion in 2014 from $20.3 billion in 2013. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 7.8% from 2014 to 2019, totaling $31.8 billion in 2019.
- The Asia-Pacific market totaled nearly $7 billion in 2013. This market is estimated to grow from $7.5 billion in 2014 to nearly $11.3 billion by 2019 at a CAGR of 8.5%.
- The European market for lung cancer totaled $6.1 billion in 2013. This market is expected to grow from $6.6 billion in 2014 to $9.5 billion by 2019 at a CAGR of 7.6%.

Introduction & Scope

INTRODUCTION
This report discusses the global lung cancer market in terms of growth, size and opportunities. The report analyzes the market for diagnostics and therapeutics for lung
cancer, and also focuses on regulations and reimbursements affecting diagnostics tests and drugs used in therapeutics. Regionally, the study focuses on North America,
Europe, Asia-Pacific and Rest of the World.

STUDY AND OBJECTIVES
- Define and discuss the global lung cancer market.
- Analyze market structure by segments and subsegments.
- Estimate market revenues of the global lung cancer market segments and subsegments by geographies and products.
- Identify market trends, issues and factors impacting lung cancer market.
- Explain opportunities in the lung cancer market with respect to geography, diagnostics and therapeutics.
- Profile major players and analyze their core competencies and strategies for the lung cancer market.
- Track alliances, joint ventures, mergers and acquisitions, new product developments, and research and development in the global lung cancer market.

TITLE DESCRIPTION
Lung cancer is the number one cancer that has fatally affected the most people in the U.S., and is more prevalent than breast, prostate and colon cancers. The survival rate
of lung cancer is extremely low; an efficient, early-stage diagnostic test has still not been identified. Tobacco smoke is the prime reason for developing lung cancer. There
are two types of lung cancer: small cell lung cancer (SCLC), which is around 15%; and non-small cell lung cancer (NSCLC), which is 85% of the total lung cancers. SCLC
cannot be operated upon, and hence the survival rate is low. NSCLC is the more common of the two types of lung cancer, and its growth is slower compared to the
SCLC. It is of three types as per the cell structure: squamous cell carcinoma, adenocarcinoma and the large cell carcinoma.

SCOPE OF THE REPORT
The report will analyze the lung cancer market as per diagnostics and therapeutics, and will also focus on the regulations and government supported programs impacting
this market. Regionally, the focus of study will be the markets of North America, Europe, Asia-Pacific and Rest of the World (ROW). This report includes various lung cancer diagnostics tests like histology/cytology, immunoassays, flow cytometry, rapid tests, molecular assays, tissue arrays, circulating tumor cells, pharmacodiagnostics, and molecular biomarkers, etc. Lung cancer therapeutics include chemotherapy, radiotherapy and surgery.

MARKET STRUCTURE
The global lung cancer markets analyzed in the report include the competitive landscape and profiles of key players of the lung cancer market as well as regional and
product analysis. The global lung cancer market is also broken down by the diagnostics and therapeutics market.

INTENDED AUDIENCE
- Equipment distributors, hospitals and other healthcare service providers.
- Life sciences companies and diagnostic laboratories.
- Research institutes, associations and academicians.

RESEARCH METHODOLOGY
A top-down approach was taken to estimate the size of the lung cancer market. To calculate market sizes, the following details were taken into account:
- Revenues of the lung cancer market are determined through primary and secondary research, including a study of the annual reports of listed market players.
- Secondary research includes a general search by keywords through paid sources such as Factiva as well as other publicly available websites and company websites.
- Micro markets are estimated through primary and secondary sources, and validated through primary sources.
- Forecasts are based on the analysis of market trends, market dynamics and strategies of key companies.
- Geographic estimates are derived from secondary sources verified through primary sources.

Table Of Contents

Diagnostics and Therapeutics for Lung Cancer: Global Markets
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 2
STUDY AND OBJECTIVES 2
TITLE DESCRIPTION 2
SCOPE OF THE REPORT 2
MARKET STRUCTURE 3
INTENDED AUDIENCE 3
RESEARCH METHODOLOGY 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 4
DISCLAIMER 4
CHAPTER 2 EXECUTIVE SUMMARY 6
SCOPE OF LUNG CANCER 6
LUNG CANCER EPIDEMIOLOGY TRENDS 6
CURRENT DIAGNOSTICS AND THERAPEUTIC TREATMENTS OF LUNG CANCER 7
UNMET MARKET NEEDS 7
RESEARCH AND DEVELOPMENT (RandD) TRENDS 7
PIPELINE ANALYSIS 8
SUMMARY TABLE GLOBAL MARKET FOR LUNG CANCER, THROUGH 2019 ($
MILLIONS) 8
SUMMARY FIGURE GLOBAL MARKET FOR LUNG CANCER, 2013-2019 ($ MILLIONS) 8
CHAPTER 3 MARKET OVERVIEW 11
MARKET DEFINITION AND GLOBAL CANCER STATISTICS 11
CANCER DIAGNOSIS AND THERAPY MANAGEMENT 11
LUNG CANCER OVERVIEW AND STATISTICS 12
TYPES AND STAGES OF LUNG CANCER 12
NON-SMALL CELL LUNG CANCER (NSCLC) 13
Staging of NSCLC 13
SMALL CELL LUNG CANCER (SCLC) 14
Staging of SCLC 14
LUNG CANCER DIAGNOSIS AND THERAPY MANAGEMENT 14
MARKET ISSUES RELATED TO LUNG CANCER 16
HIGH DRUG COST 16
DRUG APPROVAL TIMELINE 16
DRUG RESISTANCE TO CANCER DRUGS 17
NOT ENOUGH PATIENTS IN CLINICAL TRIALS 17
FEDERAL EXPENDITURE 18
FIGURE 1 CANCER RESEARCH FUNDING, 2012 (DOLLARS PER LIFE COST) 18
FIGURE 2 FEDERAL FUNDING BY CANCER SITE, 2012 ($ MILLIONS) 18
FIGURE 3 FIVE-YEAR SURVIVAL RATES BY YEAR OF DIAGNOSIS (%) 19
RECESSION IN THE GLOBAL ECONOMY 20
INNOVATIONS IN METHODS OF DIAGNOSTICS AND THERAPEUTICS OF LUNG
CANCER 20
LUNG CANCER MARKET ANALYSIS 21
NICE LIMITS THE USE OF ROCHE'S TARCEVA IN LUNG CANCER 21
ELI LILLY'S ALMITA LOSES PATENT WAR IN THE U.K. 21
FOCUS IS ON INCREASING DIFFERENTIATION BETWEEN THE THREE MAIN
NSCLC SUBTYPES 22
DRUG RESISTANCE TO THERAPIES 22
USE OF LOW-DOSE COMPUTED TOMOGRAPHY TO DETECT EARLY-STAGE
LUNG CANCER 22
LUNG CANCER IN NON-SMOKERS 22
ASTRAZENECA'S MEDI4736, A VERY VIABLE DRUG FOR TREATING LUNG
CANCER 22
LUNG CANCER MARKET STRATEGIES 23
MARKET SHARE OF KEY COMPANIES 24
FIGURE 4 MARKET SHARE OF KEY COMPANIES IN THE LUNG CANCER DIAGNOSTICS
MARKET, 2014 (%) 24
GLOBAL MARKET FOR LUNG CANCER 25
TABLE 1 GLOBAL MARKET FOR LUNG CANCER BY TYPE, THROUGH 2019 ($
MILLIONS) 25
REGULATIONS 26
UNITED STATES 26
FIGURE 5 DRUG DISCOVERY AND DEVELOPMENT TIMELINE 27
CANADA 28
EUROPE 29
Nationalized Procedure 29
Mutual Recognition Procedure (MRP) 29
FIGURE 6 MUTUAL RECOGNITION PROCEDURE 30
Decentralized Procedure 30
FIGURE 7 DECENTRALIZED PROCEDURE 31
Centralized Procedure 31
INDIA 32
FIGURE 8 DRUG APPROVAL PROCESS IN INDIA 32
CHINA 33
Step 1: Application for Approval of Clinical Study (Clinical Trial or
Bio-Efficacy Study) 34
FIGURE 9 DRUG APPROVAL PROCESS IN CHINA 34
Step 2: Conducting Clinical Studies 35
FIGURE 10 PROCEDURE FOR CLINICAL STUDIES 35
Step 3: Final Approval for Drug Registration (After Clinical Studies) 36
FIGURE 11 FINAL APPROVAL FOR DRUG REGISTRATION 36
AFRICA 36
GOVERNMENT-SUPPORTED PROGRAMS 38
UNITED STATES 38
CANADA 39
EUROPE 40
INDIA 41
CHINA 42
AFRICA 42
COMMERCIALIZING NEXT-GENERATION CANCER TESTS 43
FIGURE 12 PENETRANCE BREAKDOWN OF NEXT-GENERATION SEQUENCING TESTS,
2013 (%) 44
CURRENT MARKET SCENARIO 45
REGULATORY REQUIREMENTS OF CANCER TESTS 46
REIMBURSEMENT CODING IN THE U.S. 48
ICD 48
GENE PATENTS AND TEST COMMERCIALIZATION 49
GENE PATENTING 50
FIGURE 13 BREAKDOWN OF GENETIC TESTS MARKET, 2013 (%) 52
MAJOR COMPANIES IN THE GENETICS SERVICES MARKET 53
IMPACT OF COMPANION TEST DEVELOPMENT 54
CONCLUSIONS AND STRATEGIC IMPLICATIONS 55
UNMET MARKET NEEDS 55
PIPELINE ANALYSIS 56
CHAPTER 4 LUNG CANCER DIAGNOSTICS MARKET 60
OVERVIEW 60
TABLE 2 GLOBAL MARKET FOR LUNG CANCER DIAGNOSTICS BY REGION,
THROUGH 2019 ($ MILLIONS) 60
TABLE 3 GLOBAL MARKET FOR LUNG CANCER DIAGNOSTICS BY DIAGNOSTIC TEST,
THROUGH 2019 ($ MILLIONS) 61
RESEARCH AND DEVELOPMENT 61
INNOVATIONS 62
TRENDS 63
REGULATIONS 63
COMPETITIVE LANDSCAPE 63
HISTOLOGY/CYTOLOGY 63
MARKET OVERVIEW 63
TABLE 4 GLOBAL MARKET FOR HISTOLOGY/CYTOLOGY BY REGION, THROUGH 2019
($ MILLIONS) 64
COMPETITIVE LANDSCAPE 64
IMMUNOASSAYS 66
MARKET OVERVIEW 66
TABLE 5 GLOBAL MARKET FOR IMMUNOASSAYS BY REGION, THROUGH 2019 ($
MILLIONS) 66
COMPETITIVE LANDSCAPE 67
FLOW CYTOMETRY 68
MARKET OVERVIEW 68
TABLE 6 GLOBAL MARKET FOR FLOW CYTOMETRY BY REGION, THROUGH 2019 ($
MILLIONS) 68
COMPETITIVE LANDSCAPE 69
RAPID TESTS 70
MARKET OVERVIEW 70
TABLE 7 GLOBAL MARKET FOR RAPID TESTS BY REGION, THROUGH 2019 ($
MILLIONS) 70
COMPETITIVE LANDSCAPE 70
TABLE 8 LIST OF ALERE TEST PRODUCTS 71
MOLECULAR ASSAYS 72
MARKET OVERVIEW 72
TABLE 9 GLOBAL MARKET FOR MOLECULAR ASSAYS BY REGION, THROUGH 2019
($ MILLIONS) 72
COMPETITIVE LANDSCAPE 73
TABLE 10 MYRIAD GENETICS TESTS 74
TISSUE ARRAYS 74
MARKET OVERVIEW 74
TABLE 11 GLOBAL MARKET FOR TISSUE ARRAYS BY REGION, THROUGH 2019 ($
MILLIONS) 74
COMPETITIVE LANDSCAPE 75
CIRCULATING TUMOR CELLS 76
MARKET OVERVIEW 76
TABLE 12 GLOBAL MARKET FOR CIRCULATING TUMOR CELLS BY REGION,
THROUGH 2019 ($ MILLIONS) 77
COMPETITIVE LANDSCAPE 77
PHARMACODIAGNOSTICS, MOLECULAR 78
MARKET OVERVIEW 78
TABLE 13 GLOBAL MARKET FOR PHARMACODIAGNOSTICS, MOLECULAR BY REGION,
THROUGH 2019 ($ MILLIONS) 79
COMPETITIVE LANDSCAPE 79
BIOMARKERS 80
MARKET OVERVIEW 80
TABLE 14 GLOBAL MARKET FOR BIOMARKERS BY REGION, THROUGH 2019 ($
MILLIONS) 80
COMPETITIVE LANDSCAPE 81
OTHER DIAGNOSTICS METHODS 81
DIGITAL PCR 81
Market Overview 81
Competitive Landscape 82
MASS SPECTROMETRY 83
Market Overview 83
Competitive Landscape 83
CHROMOSOME ANALYSIS 86
Market Overview 86
Competitive Landscape 86
NEXT-GENERATION SEQUENCING 86
Market Overview 86
Competitive Landscape 87
SAMPLE PREPARATION AND SYSTEM AUTOMATION 88
Market Overview 88
Competitive Landscape 89
ROLE OF IN VIVO CELLULAR AND MOLECULAR IMAGING 90
Market Overview 90
Competitive Landscape 91
CHAPTER 5 LUNG CANCER THERAPEUTICS MARKET 94
OVERVIEW 94
TABLE 15 GLOBAL MARKET FOR LUNG CANCER THERAPEUTICS BY REGION,
THROUGH 2019 ($ MILLIONS) 94
TABLE 16 GLOBAL MARKET FOR LUNG CANCER THERAPEUTICS BY THERAPY TYPE,
THROUGH 2019 ($ MILLIONS) 94
FIGURE 14 PREVALENCE OF LUNG CANCER BY TYPE, 2014 (%) 95
CHEMOTHERAPY 95
TABLE 17 GLOBAL MARKET FOR LUNG CANCER CHEMOTHERAPY BY REGION,
THROUGH 2019 ($ MILLIONS) 96
DIFFERENT CONDITIONS IN CHEMOTHERAPY 96
FIGURE 15 BREAKDOWN OF LUNG CANCER DIAGNOSIS BY STAGE, 2004-2010 (%) 96
Chemotherapy after Surgery 97
Chemotherapy and Radiotherapy 97
Chemotherapy for Locally Advanced NSCLC or Cancer that Has
Spread 97
CHEMOTHERAPY DRUGS 97
LOW-COST DESTINATION FOR CHEMOTHERAPY 98
TABLE 18 COST COMPARISON OF LUNG CANCER TREATMENTS IN THE U.S. AND
INDIA ($) 98
INCREASING NUMBER OF LUNG CANCER PATIENTS IN THE U.S. 98
FIGURE 16 NUMBER OF CANCER CASES IN THE U.S. BY TYPE, 2014 (NUMBER OF
CASES) 98
RADIOTHERAPY 99
TABLE 19 RADIATION THERAPY AND COST IN THE U.S., 2014 ($) 100
LINEAR ACCELERATOR RADIOTHERAPY MACHINES 100
PROTON THERAPY 101
PARTICLE THERAPY 101
FIGURE 17 ADVANTAGES AND DISADVANTAGES OF PARTICLE THERAPY 102
RADIOTHERAPY MACHINES MUST NOT BE OUTDATED 102
RADIOTHERAPY TO INCREASE GLOBALLY 102
TABLE 20 GLOBAL MARKET FOR LUNG CANCER RADIOTHERAPY BY REGION,
THROUGH 2019 ($ MILLIONS) 103
SURGERY 103
TABLE 21 GLOBAL MARKET FOR LUNG CANCER SURGERY BY REGION, THROUGH
2019 ($ MILLIONS) 103
TYPES OF SURGERY 104
FIGURE 18 GLOBAL MARKET SHARE FOR LUNG CANCER SURGERY BY TYPE, 2014
(%) 104
Thoracotomy 105
Robotic Surgery 105
Video-Assisted Thoracoscopic Surgery (VATS) 105
GEOGRAPHICAL ANALYSIS OF LUNG CANCER SURGERIES 105
The U.S. 106
Europe 106
The U.K 106
APAC 107
CHAPTER 6 COMPETITIVE LANDSCAPE 109
FIGURE 19 TOP STRATEGIC ACTIVITIES OF KEY COMPANIES, 2011-NOVEMBER 2014
(NUMBER) 109
TABLE 22 PRODUCT LAUNCHES AND APPROVALS IN THE LUNG CANCER MARKET,
2011 TO 2014 110
TABLE 23 AGREEMENTS AND EXPANSIONS IN LUNG CANCER MARKET, 2011 TO
2014 119
TABLE 24 MERGERS AND ACQUISITIONS AND OTHER STRATEGIES IN THE LUNG
CANCER MARKET, 2011 TO 2014 125
CHAPTER 7 COMPANY PROFILES 130
ABBOTT LABORATORIES 130
TABLE 25 ABBOTT'S PRODUCT PORTFOLIO 130
TABLE 26 ABBOTT'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 130
ACCURAY INC. 131
TABLE 27 ACCURAY'S PRODUCT PORTFOLIO 132
TABLE 28 ACCURAY'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 132
AGILENT TECHNOLOGIES 134
TABLE 29 AGILENT'S PRODUCT PORTFOLIO 134
TABLE 30 AGILENT'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 135
ARRAY BIOPHARMA 137
TABLE 31 ARRAY BIOPHARMA'S PRODUCT PORTFOLIO 137
TABLE 32 ARRAY BIOPHARMA'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER
2014 138
ASURAGEN, INC. 138
TABLE 33 ASURAGEN'S PRODUCT PORTFOLIO 139
TABLE 34 ASURAGEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 139
BECKMAN COULTER, INC. 139
TABLE 35 BECKMAN COULTERS PRODUCT PORTFOLIO 140
BECTON DICKINSON 140
TABLE 36 BECTON DICKINSON'S PRODUCT PORTFOLIO 140
TABLE 37 BECTON DICKINSON'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER
2014 141
BIOMERIEUX 142
TABLE 38 BIOMERIEUX'S PRODUCT PORTFOLIO 142
TABLE 39 BIOMERIEUX'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 143
BIO-RAD LABORATORIES 143
TABLE 40 BIO-RAD'S PRODUCT PORTFOLIO 144
TABLE 41 BIO-RAD'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 144
BOEHRINGER INGELHEIM 146
TABLE 42 BOEHRINGER INGELHEIM'S PRODUCT PORTFOLIO 147
TABLE 43 BOEHRINGER INGELHEIM'S RECENT DEVELOPMENTS, 2011 TO
NOVEMBER 2014 147
BRUKER CORPORATION 148
TABLE 44 BRUKER'S PRODUCT PORTFOLIO 149
TABLE 45 BRUKER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 149
COVIDIEN PLC 149
TABLE 46 COVIDIEN'S PRODUCT PORTFOLIO 150
TABLE 47 COVIDIEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 150
DAKO DENMARK A/S 152
TABLE 48 DAKO'S PRODUCT PORTFOLIO 152
TABLE 49 DAKO'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO
NOVEMBER 2014 152
DANAHER CORPORATION 153
TABLE 50 DANAHER'S PRODUCT PORTFOLIO 153
ELI LILLY 153
TABLE 51 ELI LILLY'S PRODUCT PORTFOLIO 154
TABLE 52 ELI LILLY'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 155
ETHICON ENDO-SURGERY INC. 155
TABLE 53 ETHICON'S PRODUCT PORTFOLIO 156
TABLE 54 ETHICON'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 156
HOLOGIC 157
TABLE 55 HOLOGIC'S PRODUCT PORTFOLIO 158
TABLE 56 HOLOGIC'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 158
MERCK MILLIPORE 159
TABLE 57 MERCK MILLIPORE PRODUCT PORTFOLIO 159
TABLE 58 MERCK MILLIPORE RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 159
OLYMPUS CORP. 160
TABLE 59 OLYMPUS' PRODUCT PORTFOLIO 160
PFIZER 160
TABLE 60 PFIZER'S PRODUCT PORTFOLIO 161
TABLE 61 PFIZER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 161
QIAGEN 162
TABLE 62 QIAGEN'S PRODUCT PORTFOLIO 163
TABLE 63 QIAGEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 163
RAYBIOTECH 165
TABLE 64 RAYBIOTECH'S PRODUCT PORTFOLIO 166
TABLE 65 RAYBIOTECH'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011
TO NOVEMBER 2014 166
ROCHE DIAGNOSTICS 166
TABLE 66 ROCHE DIAGNOSTICS' PRODUCT PORTFOLIO 167
TABLE 67 ROCHE DIAGNOSTICS' RECENT DEVELOPMENTS, 2011 TO NOVEMBER
2014 167
SIEMENS HEALTHCARE 169
TABLE 68 SIEMENS HEALTHCARE'S PRODUCT PORTFOLIO 169
TABLE 69 SIEMENS HEALTHCARE'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER
2014 170
SIGMA ALDRICH 170
TABLE 70 SIGMA-ALDRICH'S PRODUCT PORTFOLIO 171
TABLE 71 SIGMA-ALDRICH'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS,
2011 TO NOVEMBER 2014 171
THERMO FISHER SCIENTIFIC 171
TABLE 72 THERMO FISHER'S PRODUCT PORTFOLIO 172
TABLE 73 THERMO FISHER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 172
TRANSGENE SA 172
TABLE 74 TRANSGENE'S PRODUCT PORTFOLIO 173
TABLE 75 TRANSGENE'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 173
TRINITY BIOTECH 174
TABLE 76 TRINITY'S PRODUCT PORTFOLIO 174
CHAPTER 8 PATENT ANALYSIS 176
FIGURE 20 NUMBER OF PATENTS BY REGION, 2011 TO NOVEMBER 2014 (NUMBER) 176
LIST OF PATENTS 177
UNITED STATES 177
TABLE 77 U.S. PATENTS, 2011 TO NOVEMBER 2014 177
EUROPE 180
TABLE 78 EUROPE'S PATENTS, 2011 TO NOVEMBER 2014 180
JAPAN 185
TABLE 79 JAPAN'S PATENTS, 2010 TO NOVEMBER 2014 185

LIST OF TABLES
SUMMARY TABLE GLOBAL MARKET FOR LUNG CANCER, THROUGH 2019 ($ MILLIONS) 8
TABLE 1 GLOBAL MARKET FOR LUNG CANCER BY TYPE, THROUGH 2019 ($ MILLIONS) 25
TABLE 2 GLOBAL MARKET FOR LUNG CANCER DIAGNOSTICS BY REGION, THROUGH
2019 ($ MILLIONS) 60
TABLE 3 GLOBAL MARKET FOR LUNG CANCER DIAGNOSTICS BY DIAGNOSTIC TEST,
THROUGH 2019 ($ MILLIONS) 61
TABLE 4 GLOBAL MARKET FOR HISTOLOGY/CYTOLOGY BY REGION, THROUGH 2019
($ MILLIONS) 64
TABLE 5 GLOBAL MARKET FOR IMMUNOASSAYS BY REGION, THROUGH 2019 ($
MILLIONS) 66
TABLE 6 GLOBAL MARKET FOR FLOW CYTOMETRY BY REGION, THROUGH 2019 ($
MILLIONS) 68
TABLE 7 GLOBAL MARKET FOR RAPID TESTS BY REGION, THROUGH 2019 ($
MILLIONS) 70
TABLE 8 LIST OF ALERE TEST PRODUCTS 71
TABLE 9 GLOBAL MARKET FOR MOLECULAR ASSAYS BY REGION, THROUGH 2019 ($
MILLIONS) 72
TABLE 10 MYRIAD GENETICS TESTS 74
TABLE 11 GLOBAL MARKET FOR TISSUE ARRAYS BY REGION, THROUGH 2019 ($
MILLIONS) 74
TABLE 12 GLOBAL MARKET FOR CIRCULATING TUMOR CELLS BY REGION, THROUGH
2019 ($ MILLIONS) 77
TABLE 13 GLOBAL MARKET FOR PHARMACODIAGNOSTICS, MOLECULAR BY REGION,
THROUGH 2019 ($ MILLIONS) 79
TABLE 14 GLOBAL MARKET FOR BIOMARKERS BY REGION, THROUGH 2019 ($
MILLIONS) 80
TABLE 15 GLOBAL MARKET FOR LUNG CANCER THERAPEUTICS BY REGION,
THROUGH 2019 ($ MILLIONS) 94
TABLE 16 GLOBAL MARKET FOR LUNG CANCER THERAPEUTICS BY THERAPY TYPE,
THROUGH 2019 ($ MILLIONS) 94
TABLE 17 GLOBAL MARKET FOR LUNG CANCER CHEMOTHERAPY BY REGION,
THROUGH 2019 ($ MILLIONS) 96
TABLE 18 COST COMPARISON OF LUNG CANCER TREATMENTS IN THE U.S. AND
INDIA ($) 98
TABLE 19 RADIATION THERAPY AND COST IN THE U.S., 2014 ($) 100
TABLE 20 GLOBAL MARKET FOR LUNG CANCER RADIOTHERAPY BY REGION,
THROUGH 2019 ($ MILLIONS) 103
TABLE 21 GLOBAL MARKET FOR LUNG CANCER SURGERY BY REGION, THROUGH
2019 ($ MILLIONS) 103
TABLE 22 PRODUCT LAUNCHES AND APPROVALS IN THE LUNG CANCER MARKET,
2011 TO 2014 110
TABLE 23 AGREEMENTS AND EXPANSIONS IN LUNG CANCER MARKET, 2011 TO 2014 119
TABLE 24 MERGERS AND ACQUISITIONS AND OTHER STRATEGIES IN THE LUNG
CANCER MARKET, 2011 TO 2014 125
TABLE 25 ABBOTT'S PRODUCT PORTFOLIO 130
TABLE 26 ABBOTT'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 130
TABLE 27 ACCURAY'S PRODUCT PORTFOLIO 132
TABLE 28 ACCURAY'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 132
TABLE 29 AGILENT'S PRODUCT PORTFOLIO 134
TABLE 30 AGILENT'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 135
TABLE 31 ARRAY BIOPHARMA'S PRODUCT PORTFOLIO 137
TABLE 32 ARRAY BIOPHARMA'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 138
TABLE 33 ASURAGEN'S PRODUCT PORTFOLIO 139
TABLE 34 ASURAGEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 139
TABLE 35 BECKMAN COULTERS PRODUCT PORTFOLIO 140
TABLE 36 BECTON DICKINSON'S PRODUCT PORTFOLIO 140
TABLE 37 BECTON DICKINSON'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER
2014 141
TABLE 38 BIOMERIEUX'S PRODUCT PORTFOLIO 142
TABLE 39 BIOMERIEUX'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 143
TABLE 40 BIO-RAD'S PRODUCT PORTFOLIO 144
TABLE 41 BIO-RAD'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 144
TABLE 42 BOEHRINGER INGELHEIM'S PRODUCT PORTFOLIO 147
TABLE 43 BOEHRINGER INGELHEIM'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER
2014 147
TABLE 44 BRUKER'S PRODUCT PORTFOLIO 149
TABLE 45 BRUKER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 149
TABLE 46 COVIDIEN'S PRODUCT PORTFOLIO 150
TABLE 47 COVIDIEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 150
TABLE 48 DAKO'S PRODUCT PORTFOLIO 152
TABLE 49 DAKO'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011 TO
NOVEMBER 2014 152
TABLE 50 DANAHER'S PRODUCT PORTFOLIO 153
TABLE 51 ELI LILLY'S PRODUCT PORTFOLIO 154
TABLE 52 ELI LILLY'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 155
TABLE 53 ETHICON'S PRODUCT PORTFOLIO 156
TABLE 54 ETHICON'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 156
TABLE 55 HOLOGIC'S PRODUCT PORTFOLIO 158
TABLE 56 HOLOGIC'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 158
TABLE 57 MERCK MILLIPORE PRODUCT PORTFOLIO 159
TABLE 58 MERCK MILLIPORE RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 159
TABLE 59 OLYMPUS' PRODUCT PORTFOLIO 160
TABLE 60 PFIZER'S PRODUCT PORTFOLIO 161
TABLE 61 PFIZER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 161
TABLE 62 QIAGEN'S PRODUCT PORTFOLIO 163
TABLE 63 QIAGEN'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 163
TABLE 64 RAYBIOTECH'S PRODUCT PORTFOLIO 166
TABLE 65 RAYBIOTECH'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS, 2011
TO NOVEMBER 2014 166
TABLE 66 ROCHE DIAGNOSTICS' PRODUCT PORTFOLIO 167
TABLE 67 ROCHE DIAGNOSTICS' RECENT DEVELOPMENTS, 2011 TO NOVEMBER
2014 167
TABLE 68 SIEMENS HEALTHCARE'S PRODUCT PORTFOLIO 169
TABLE 69 SIEMENS HEALTHCARE'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER
2014 170
TABLE 70 SIGMA-ALDRICH'S PRODUCT PORTFOLIO 171
TABLE 71 SIGMA-ALDRICH'S RECENT DEVELOPMENTS RECENT DEVELOPMENTS,
2011 TO NOVEMBER 2014 171
TABLE 72 THERMO FISHER'S PRODUCT PORTFOLIO 172
TABLE 73 THERMO FISHER'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 172
TABLE 74 TRANSGENE'S PRODUCT PORTFOLIO 173
TABLE 75 TRANSGENE'S RECENT DEVELOPMENTS, 2011 TO NOVEMBER 2014 173
TABLE 76 TRINITY'S PRODUCT PORTFOLIO 174
TABLE 77 U.S. PATENTS, 2011 TO NOVEMBER 2014 177
TABLE 78 EUROPE'S PATENTS, 2011 TO NOVEMBER 2014 180
TABLE 79 JAPAN'S PATENTS, 2010 TO NOVEMBER 2014 185

LIST OF FIGURES
SUMMARY FIGURE GLOBAL MARKET FOR LUNG CANCER, 2013-2019 ($ MILLIONS) 8
FIGURE 1 CANCER RESEARCH FUNDING, 2012 (DOLLARS PER LIFE COST) 18
FIGURE 2 FEDERAL FUNDING BY CANCER SITE, 2012 ($ MILLIONS) 18
FIGURE 3 FIVE-YEAR SURVIVAL RATES BY YEAR OF DIAGNOSIS (%) 19
FIGURE 4 MARKET SHARE OF KEY COMPANIES IN THE LUNG CANCER DIAGNOSTICS
MARKET, 2014 (%) 24
FIGURE 5 DRUG DISCOVERY AND DEVELOPMENT TIMELINE 27
FIGURE 6 MUTUAL RECOGNITION PROCEDURE 30
FIGURE 7 DECENTRALIZED PROCEDURE 31
FIGURE 8 DRUG APPROVAL PROCESS IN INDIA 32
FIGURE 9 DRUG APPROVAL PROCESS IN CHINA 34
FIGURE 10 PROCEDURE FOR CLINICAL STUDIES 35
FIGURE 11 FINAL APPROVAL FOR DRUG REGISTRATION 36
FIGURE 12 PENETRANCE BREAKDOWN OF NEXT-GENERATION SEQUENCING TESTS,
2013 (%) 44
FIGURE 13 BREAKDOWN OF GENETIC TESTS MARKET, 2013 (%) 52
FIGURE 14 PREVALENCE OF LUNG CANCER BY TYPE, 2014 (%) 95
FIGURE 15 BREAKDOWN OF LUNG CANCER DIAGNOSIS BY STAGE, 2004-2010 (%) 96
FIGURE 16 NUMBER OF CANCER CASES IN THE U.S. BY TYPE, 2014 (NUMBER OF
CASES) 98
FIGURE 17 ADVANTAGES AND DISADVANTAGES OF PARTICLE THERAPY 102
FIGURE 18 GLOBAL MARKET SHARE FOR LUNG CANCER SURGERY BY TYPE, 2014 (%) 104
FIGURE 19 TOP STRATEGIC ACTIVITIES OF KEY COMPANIES, 2011-NOVEMBER 2014
(NUMBER) 109
FIGURE 20 NUMBER OF PATENTS BY REGION, 2011 TO NOVEMBER 2014 (NUMBER) 176

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

Prescription barriers hurt 5 of the 9 brands we surveyed. Is your brand losing market share? In the EU5, one of the most prescribed NSCLC drugs is stuck in 2nd place due to the biggest barrier-related ...

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

7 of the 10 brands we surveyed lose share due to market barriers. Is your brand one of them? In the US, market barriers are causing 7 of the 10 NSCLC drugs we surveyed to lose market share. What’s ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Cancer Statistics in the UK

  • November 2016
    10 pages
  • Cancer  

  • United Kingdom  

View report >

Pollution Control Statistics in the US

  • November 2016
    218 pages
  • Pollution Contr...  

    Cancer  

    Metals  

  • United States  

    North America  

View report >

Related Market Segments :

Lung Cancer

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.